Background: Once recurrent or persistent locoregional tumour after radical chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) is identified, few curative-intent treatment options are available. Selected patients might benefit from surgical salvage. We performed a systematic review of the available literature for this emerging treatment option.
Methods: A systematic literature search was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Publications about persistent or (locoregional) recurrent disease after radical/definitive CRT for locally advanced non-small cell lung cancer were identified.
Results: Eight full papers were found, representing 158 patients. All were retrospective series and data were heterogeneous: definition and indication for salvage surgery varied and the median time from radiotherapy to surgery was 4.1-33 months. Complete resection (R0) was achieved in 85-100%, with vital tumour in 61-100%. A large number of pneumonectomies were performed, and additional structures were often resected. Where reported, 90-day mortality was 0-11.4%. Reported survival metrics varied but included median overall survival 9-46 months and 5-year survival 20-75%.
Conclusion: There are limited, low-level, heterogeneous data in support of salvage surgery after radical CRT. Based on this, perioperative mortality appears acceptable and long-term survival is possible in (highly) selected patients. In suitable patients (fit, no distant metastases, tumour appears completely resectable and preferably with confirmed viable tumour), this treatment option should be discussed in an experienced multidisciplinary lung cancer team.
Keywords: chemoradiotherapy; non-small cell lung cancer (NSCLC); recurrence; salvage; surgery.
Conflict of interest statement
Conflict of interest statement: MD has received research funding and honoraria/travel support from Varian Medical Systems (Palo Alto, California, USA).
Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.Lung Cancer. 2016 Apr;94:108-13. doi: 10.1016/j.lungcan.2016.02.005. Epub 2016 Feb 11. Lung Cancer. 2016. PMID: 26973215
Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review.Ther Adv Med Oncol. 2018 Jul 13;10:1758835918787989. doi: 10.1177/1758835918787989. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30023008 Free PMC article.
Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.Thorac Cardiovasc Surg. 2018 Mar;66(2):135-141. doi: 10.1055/s-0037-1606597. Epub 2017 Oct 9. Thorac Cardiovasc Surg. 2018. PMID: 28992654
Salvage surgery after high-dose radiotherapy.J Thorac Dis. 2017 Apr;9(Suppl 3):S193-S200. doi: 10.21037/jtd.2017.03.88. J Thorac Dis. 2017. PMID: 28446984 Free PMC article. Review.
Critical appraisal of the 'wait and see' approach in rectal cancer for clinical complete responders after chemoradiation.Br J Surg. 2012 Jul;99(7):897-909. doi: 10.1002/bjs.8732. Epub 2012 Apr 27. Br J Surg. 2012. PMID: 22539154 Review.
Cited by 2 articles
Surgery to avoid fatal complications and secure radicality after definitive chemoradiotherapy for clinical T4N2M0 stage IIIB non-small cell lung cancer: a case report.Surg Case Rep. 2020 Jan 13;6(1):16. doi: 10.1186/s40792-019-0768-5. Surg Case Rep. 2020. PMID: 31933045 Free PMC article.
Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells.Int J Biol Sci. 2019 Mar 1;15(4):826-837. doi: 10.7150/ijbs.31749. eCollection 2019. Int J Biol Sci. 2019. PMID: 30906213 Free PMC article.
- Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1–iv21. - PubMed
- Van der Drift MA, Karim-Kos HE, Siesling S, et al. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol 2012; 7: 291–298. - PubMed
- Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187–199. - PMC - PubMed
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1–e34. - PubMed
- Bauman JE, Mulligan MS, Martins RG, et al. Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg 2008; 86: 1632–1638. - PubMed